Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.88 -2.3%	$3.34	$1.07 ▼ $4.08	$1.04B	0.88	3.16 million shs	2.87 million shs
AVDL Avadel Pharmaceuticals	$10.38 +3.4%	$9.28	$6.38 ▼ $17.30	$971.26M	1.42	1.23 million shs	977,072 shs
ETNB 89BIO	$10.51 -5.5%	$9.56	$4.16 ▼ $11.84	$1.62B	1.28	1.53 million shs	1.21 million shs
MRNS Marinus Pharmaceuticals	$0.55 -0.2%	$0.55	$0.22 ▼ $1.97	$30.32M	1.03	1.89 million shs	260 shs
WVE WAVE Life Sciences	$7.71 -1.7%	$6.71	$5.04 ▼ $16.74	$1.22B	-1.01	1.30 million shs	1.45 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+1.02%	+9.37%	+11.52%	+110.05%	+215.08%
AVDL Avadel Pharmaceuticals	+4.47%	+12.94%	+4.91%	+26.93%	-39.52%
ETNB 89BIO	+1.09%	+8.81%	+6.82%	+83.80%	+26.65%
MRNS Marinus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-59.92%
WVE WAVE Life Sciences	+1.82%	+11.05%	+12.81%	+24.84%	+39.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.6514 of 5 stars	3.6	1.0	4.0	2.0	0.8	0.6
AVDL Avadel Pharmaceuticals	1.8309 of 5 stars	3.5	1.0	0.0	1.5	1.7	0.6
ETNB 89BIO	2.0838 of 5 stars	3.5	1.0	0.0	3.2	0.8	0.6
MRNS Marinus Pharmaceuticals	2.0554 of 5 stars	3.2	0.0	4.2	0.0	1.7	0.6
WVE WAVE Life Sciences	4.4262 of 5 stars	3.5	2.0	4.8	1.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	73.97% Upside
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	75.02% Upside
ETNB 89BIO	3.00	Buy	$26.43	151.46% Upside
MRNS Marinus Pharmaceuticals	2.40	Hold	$3.92	613.29% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	165.89% Upside

Current Analyst Ratings Breakdown

Latest AKBA, WVE, AVDL, ETNB, and MRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/30/2025	ETNB 89BIO	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/29/2025	WVE WAVE Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.36	N/A	N/A	($0.23) per share	-16.87
AVDL Avadel Pharmaceuticals	$169.12M	5.94	N/A	N/A	$0.77 per share	13.48
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
MRNS Marinus Pharmaceuticals	$30.99M	0.98	N/A	N/A	$0.31 per share	1.77
WVE WAVE Life Sciences	$108.30M	11.07	N/A	N/A	$1.37 per share	5.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	0.00	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	173.00	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	0.00	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
MRNS Marinus Pharmaceuticals	-$141.40M	-$2.47	N/A	N/A	N/A	-446.48%	-7,831.35%	-120.74%	8/11/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	0.00	N/A	N/A	N/A	-86.49%	-37.20%	8/14/2025 (Estimated)

Latest AKBA, WVE, AVDL, ETNB, and MRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
MRNS Marinus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
ETNB 89BIO	0.06	18.03	18.03
MRNS Marinus Pharmaceuticals	N/A	1.66	1.47
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVDL Avadel Pharmaceuticals	69.19%
ETNB 89BIO	N/A
MRNS Marinus Pharmaceuticals	98.80%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AVDL Avadel Pharmaceuticals	5.20%
ETNB 89BIO	2.80%
MRNS Marinus Pharmaceuticals	5.46%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
ETNB 89BIO	40	145.98 million	141.90 million	Optionable
MRNS Marinus Pharmaceuticals	110	55.22 million	52.20 million	Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

AKBA, WVE, AVDL, ETNB, and MRNS Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

5 hours ago | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50

July 9, 2025 | americanbankingnews.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, WVE, AVDL, ETNB, and MRNS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.88 -0.09 (-2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.10%)

As of 07:14 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Avadel Pharmaceuticals NASDAQ:AVDL

$10.38 +0.34 (+3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$10.32 -0.07 (-0.63%)

As of 07:56 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

89BIO NASDAQ:ETNB

$10.51 -0.61 (-5.49%)

Closing price 04:00 PM Eastern

Extended Trading

$10.54 +0.03 (+0.24%)

As of 04:24 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Marinus Pharmaceuticals NASDAQ:MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

WAVE Life Sciences NASDAQ:WVE

$7.71 -0.13 (-1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.55 -0.16 (-2.08%)

As of 07:42 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time